Login to Your Account

Gene therapy golden for Avexis in $127.7M public offering

By Marie Powers
News Editor

Thursday, September 8, 2016

As Bluebird Bio Inc. soaked up most of the spotlight on gene therapy by opening the global phase III trial of its Lentiglobin BB305 candidate in patients with beta-thalassemia, stealthy Avexis Inc. sought to extend its cash runway.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription